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Abstract
Background: In rural Ethiopia, 72% of women are exposed to lifetime intimate partner violence (IPV); IPV is most
prevalent during pregnancy. As well as adversely affecting women’s physical and mental health, IPV also increases the
risk of child morbidity and mortality associated with maternal depression, thus making antenatal care an important
opportunity for intervention. Adapting generic, task-shared, brief psychological interventions for perinatal depression
and anxiety to address the needs and experiences of women affected by IPV may improve acceptability to women
and feasibility for health workers. This randomised controlled feasibility trial will compare brief problem solving therapy
(PST) specifically adapted for pregnant women experiencing IPV (PST-IPV) with standard PST and enhanced usual care
to determine the feasibility of a future fully powered randomised controlled trial.
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Methods: Seventy-five pregnant women scoring five or more on the Patient Health Questionnaire, endorsing a tenth
question about functional impact and reporting past-year IPV, will be recruited from antenatal care clinics in
predominantly rural districts in Ethiopia. Consenting participants will be randomised to either four sessions of PST-IPV, four
sessions of standard PST or information about sources of support (enhanced usual care) in a three-arm design. The
interventions will be delivered by trained, supervised antenatal care staff using a task-sharing model. Assessments will be
made at baseline and after 9 weeks by masked outcome assessors and will include measures of depression symptoms
(primary outcome), post-traumatic stress, anxiety symptoms, functional impact, past-month IPV and hypothesised
mediators (secondary outcomes). A mixed-method process evaluation will determine the feasibility of a future
randomised controlled trial, assess the feasibility, acceptability, fidelity and quality of implementation of PST-IPV, generate
testable hypotheses about causal mechanisms, and identify potential contextual factors influencing outcomes.
Discussion: Despite mental health being a critical concern for women experiencing IPV, there is limited evidence for
brief, task-shared psychological interventions adapted for their needs in low- and middle-income countries. Contextually
tailored interventions for pregnant women experiencing IPV in low- and middle-income countries require development
and process evaluation. This randomised controlled feasibility trial will yield results on the feasibility of conducting a fully
powered trial, relevant to researchers, primary and antenatal care clinicians in resource-limited settings.
Trial registration: Pan-African clinical trials registry: PACTR202002513482084. Prospectively registered on 13 December
2019.
Keywords: Global mental health, Pregnancy, Perinatal mental health, Intimate partner violence, Psychological
interventions, Task sharing, Low- and middle-income countries, Feasibility studies, Implementation research
Introduction
Background and rationale
Intimate partner violence (IPV) refers to behaviour by a
partner or ex-partner that causes (or has the potential to
cause) physical, sexual or psychological harm. IPV includes
physical aggression, sexual coercion, psychological abuse
and controlling activity [1]. It is highly prevalent worldwide
[2] and an important social determinant of physical and
mental health [3, 4]. In response, the World Health
Organization (WHO) [5], the United Nations [6] and the
World Psychiatric Association [7–9] have prioritised inter-
ventions to prevent and address IPV and its health impacts.
The relationship between IPV and mental health is bidirec-
tional, such that IPV increases a woman’s risk of mental dis-
orders, which in turn increases a woman’s vulnerability to
(further) IPV. For example, IPV is associated with subsequent
depressive symptoms, suicide attempts [10] and alcohol use
disorders [11], which increase women’s risk for IPV (re)victi-
misation. Exposure to IPV is rarely assessed in randomised
controlled trials (RCTs) of psychological interventions [12],
but some studies have found reduced IPV alongside im-
proved mental health [13] and birth outcomes [14].
There is limited evidence on mental health interventions
tailored to the needs of pregnant women experiencing IPV
[15], especially in low- and middle-income countries
(LMICs). In a rapid review of evidence, 33 studies were
identified that reported mental health interventions for
women affected by IPV [16]. In most of these studies, the
interventions were group-delivered cognitive behavioural
therapy (CBT)-informed interventions, mind–body inter-
ventions (such as mindfulness-based stress reduction, yogic
techniques and biofeedback) or individually delivered,
trauma-focused psychotherapeutic interventions. Although
all the identified studies came from high-income countries,
protocols from Tanzania [17] and South Africa [18] indi-
cated growing research interest in the African region. For
example, one RCT in Nairobi, Kenya, has shown that five
sessions of the multicomponent behavioural treatment
Problem Management Plus (PM+) delivered to women
with a history of any gender-based violence are associated
with improved psychological distress and post-traumatic
stress symptoms at 3-month follow-up compared with en-
hanced usual care [19].
A recent systematic review confirmed the paucity of
intervention research addressing the mental health of
both survivors and perpetrators of IPV in LMICs [20];
no studies replicated evaluations of previously studied
interventions and none were conducted in low-income
countries. The authors recommended strengthening
the theoretical underpinnings of mental health inter-
ventions for people experiencing or perpetrating IPV,
testing their impacts on hypothesised mediators and
improving IPV detection using continuous outcome
measures and fully powered samples. Treating de-
pression and post-traumatic stress disorder (PTSD)
has the potential to reduce self-blame, low self-
esteem, hopelessness and emotional numbing, and
improve communication, stress coping and anger
management skills among both survivors and perpe-
trators [20].
We recently investigated whether IPV exposure mod-
erates the efficacy of generic psychological interventions
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in LMICs. Our meta-analysis of 15 studies that provided
data showed that women reporting IPV demonstrated
greater improvements in anxiety symptoms than women
not reporting IPV following generic psychological inter-
ventions (difference in standardised mean differences,
0.31; 95% confidence interval 0.04–0.57; I2 49.3%) and
consistent but non-significant differences in PTSD, de-
pression and psychological distress symptom improve-
ments [21]. Our systematic review only identified two
RCTs of psychological interventions for depression or
anxiety in LMICs which were tailored for women experi-
encing IPV. In Pakistan, ten sessions of IPV-adapted
group CBT were associated with improved depression
and anxiety compared with CBT-based self-help groups
[22]. In Iran, 10–12 sessions of IPV-tailored narrative
exposure therapy were associated with improved PTSD
and depression at 3- and 6-month follow-up compared
with treatment as usual (life skills training and support-
ive counselling) [23]. These studies support the potential
benefits of adapting psychological interventions for de-
pression, anxiety or PTSD to meet the needs and experi-
ences of women affected by IPV.
Although PM+ has been shown to be effective for
women experiencing gender-based violence in Nairobi
[19], delivering five 90-min sessions may not be feasible
in primary care settings in low-income countries. Prob-
lem solving therapy (PST) is a brief psychological inter-
vention that aims to improve coping with life problems
by teaching problem solving skills. A meta-analysis of
PST for depression found a standardised mean effect
size of 0.34, but high heterogeneity among included
studies indicated the need for research to determine the
settings and patient groups for whom PST is most ef-
fective [24]. A meta-analysis of PST for any mental or
physical health problem found that it was significantly
more effective than no treatment, treatment as usual,
and ‘attention placebo’ arms (controlling for non-specific
effects of contact), moderated by the use of problem
orientation training and homework assignments [25].
Several studies from LMICs suggest that PST can be ef-
fective for treating depression, anxiety and psychological
distress. A 5-week pilot study of adapted PST in English,
Xhosa and Afrikaans in South African township residents
found that it was acceptable, feasible and associated with
significant reductions in psychological distress [26]. An
RCT of South African emergency department attendees
found that substance use was significantly reduced at 3-
month follow-up in participants who received five sessions
of blended PST and motivational interviewing, compared
to motivational interviewing alone or psychoeducation
control [27]. In Zimbabwe, the ‘Friendship Bench’ inter-
vention comprised six sessions of individual PST delivered
by lay health workers, and an optional six-session peer
support group [28]. In this 86% female sample, depression
and psychological distress were significantly reduced fol-
lowing PST in comparison to enhanced usual care.
The importance of designing RCTs to evaluate mediators
of treatment and mechanisms of change is widely sup-
ported [29]. However, despite evidence of efficacy, studies
of how PST works are limited and contradictory. Hypothe-
sised mechanisms have included improving mastery, self-
control and the accuracy of perceived problem severity
[30], problem solving skills [31], ‘life integration’ [32] and
locus of control (the extent to which the individual attri-
butes their experiences to internal or external factors) [33].
An RCT comparing online CBT, PST and waiting list con-
trol for depression found that the effects of both interven-
tions were mediated by reduced dysfunctional attitudes,
worry, negativity towards problems and increased mastery,
with no difference in effect sizes between CBT and PST
[34]. The authors postulated that both interventions in-
crease expectations of self-efficacy, leading to greater com-
mencement and continuation of coping behaviours [35].
Both mechanisms for improved mood might also influence
the ability of women to respond to IPV.
Process evaluations of complex intervention feasibility
studies are increasingly recognised as being vital to opti-
mise the safety, efficiency and validity of subsequent
RCTs [5, 36]. Updated guidance [37] and growing con-
sensus [38] support the need for studies to determine
the feasibility of research methods used to study com-
plex interventions before conducting definitive RCTs.
Sociocultural, health system and economic factors
affect the adaptation, translation, mechanisms, success
and scale-up of interventions, so a mixed-method
process evaluation [39] is crucial and helps to inform
understanding of the context for future implementa-
tion [40].
In rural Ethiopia, 72% of women are exposed to life-
time IPV [41] and this is associated with emotional dis-
tress [42] and depression [43]. IPV in Ethiopia is most
prevalent during pregnancy [44] and increases the risk
of child morbidity and mortality associated with mater-
nal depression [45]. Antenatal depression in Ethiopia is
associated with increased emergency presentations in
pregnancy [46], perinatal complications [47], prolonged
labour [48] and use of emergency delivery care [49]. As
pregnancy is the most common time for Ethiopian
women to access health care [50], antenatal care offers
an important opportunity to provide an intervention that
addresses both IPV and depression.
The range of cultural, geographical, economic, lin-
guistic, religious, socio-political, health system and
other differences between rural Ethiopia and the
largely middle-income settings of most RCTs pub-
lished to date supports the need for research evaluat-
ing PST adapted for women experiencing IPV (PST-
IPV) in this context.
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Objectives
In this randomised feasibility trial and process evaluation
of perinatal PST-IPV in rural Ethiopia, we aim to deter-
mine the feasibility and acceptability of the intervention
and study design to inform a future fully powered RCT.
Specific objectives are to:
1) Determine whether the PST-IPV intervention and
processes of recruitment, randomisation, follow-up
and evaluation are feasible and acceptable to preg-
nant women and health workers in rural Ethiopia.
This includes estimating parameters to inform the
design of a future RCT.
2) Refine the PST-IPV intervention and study design
in response to a mixed-method process evaluation,
which assesses the feasibility, acceptability, fidelity
and quality of the intervention, explores causal
mechanisms, and identifies contextual factors that
may influence outcomes [37].
Trial design
In this three-arm feasibility trial, we will randomise eli-
gible women (with depressive symptoms, functional im-
pact and past-year IPV) to PST-IPV, standard PST or
enhanced usual care (information about relevant sources
of support). All arms represent additions to standard
clinical care, which does not currently provide any rou-
tine interventions for perinatal depression or IPV.
This study is linked to a two-arm feasibility trial that
will randomise eligible women (with depressive symp-
toms and functional impact) to standard PST or infor-
mation only, the protocol of which is reported separately
(Bitew T, Keynejad RC, Honikman S, Sorsdahl K, Myers
B, Fekadu A, et al. Brief problem-solving therapy for
perinatal depression in rural Ethiopia: protocol for a ran-
domised feasibility study.) (see Fig. 1).
Methods
Study setting
The study will be conducted in selected health facilities in
the predominantly rural areas of Gurage zone (projected
population 1,712,506) and Silt’e zone (projected popula-
tion 1,043,242) in the Southern Nations, Nationalities, and
Peoples’ Region of Ethiopia [51]. Primary health care is
structured so that the nurse, midwife and health officer-
run health centres (serving a population of 25,000–40,
000) are linked to five community health posts (serving a
population of 3000–5000) staffed by one or two health
extension workers (HEWs) each, with access to a single
primary hospital for more specialist care. HEWs, who
have completed high school and received 1 year of
undergraduate-level training [52], provide a first antenatal
contact before referring women for further antenatal care
(ANC) at a health centre or primary hospital and maintain
contact with women during pregnancy.
This study builds on the programme for improving
mental health care (PRIME) study [53], which integrated
mental health into primary and maternal care in five
LMICs, including the Gurage zone, Ethiopia [54]. In
PRIME, a district-level mental health plan was developed
in collaboration with key stakeholders and comprised in-
terventions at the community, health facility and health
system level. At the facility level, PRIME trained primary
and maternal care staff using the mental health gap ac-
tion programme (mhGAP) intervention guide of the
WHO, which guides non-mental health specialists
through clinical diagnostic and treatment algorithms for
prioritised mental, neurological and substance use disor-
ders [55]. The PRIME study investigators identified low
detection rates of depression, which may be related in
part to a lack of acceptable treatment options. Formative
work was therefore conducted to inform adaptation of a
brief psychological intervention for depression. In a
nested study, PST was then adapted for antenatal
women in this rural Ethiopian setting.
A systematic review and meta-analysis [21], further
qualitative interviews and theory of change workshops
(Bitew T, Keynejad RC, Honikman S, Sorsdahl K, Myers
B, Fekadu A, et al. Brief psychological intervention for
antenatal depression: a qualitative study.) (Keynejad RC,
Bitew T, Mulushoa A, Tol W, Howard LM, Hanlon C.
Adapting brief, task-shared problem-solving therapy for
women experiencing intimate partner violence in rural
Ethiopia: a qualitative study.) were then used to adapt
this locally tailored PST intervention to address the
needs and experiences of women affected by IPV. The
preliminary theory of change visualises health worker
perspectives on the components, hypothesised media-
tors, intermediate and long-term outcomes of PST-IPV
intervention, and factors anticipated to influence the de-
livery and implementation of PST-IPV (see Supplemen-
tary file 1).
Adaptation for IPV focused on international guidelines
[5], which recommend identifying women experiencing
IPV, training health care providers about IPV, and pro-
viding woman-centred care and support when IPV is
disclosed. PST-IPV will apply a PST approach in the
context of IPV, enabling IPV-related problem solving
and management of mental health-related symptoms.
Participant sample size
As a feasibility trial, this study is not powered to detect
intervention efficacy, but rather to estimate feasibility pa-
rameters to inform a future RCT, and test intervention
and research protocols. With a total sample size of 75 (25
participants randomised to PST-IPV, 25 to PST and 25 to
enhanced usual care), a drop-out rate of 30% can be
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estimated to within a 95% confidence interval of ±3%. To
estimate the standard deviation of the primary feasibility
outcome measure to inform a future RCT sample size cal-
culation, recommended feasibility trial sample sizes range
between a total of 24 and 50 across two arms [56, 57].
Participant recruitment
Research staff will consult health care workers based in
primary hospitals and/or health centres in Gurage and
Silt’e zones to identify potentially eligible women meet-
ing those inclusion criteria about which information is
held for screening. Potentially eligible women will be
approached through ANC clinics and HEW home visits
by research staff and provided with written and verbal in-
formation in Amharic, before being invited to give written,
informed consent to initial screening. Non-literate women
will signify their consent by finger print. A high school-
educated assistant will act as a witness to confirm that the
information sheet has been read aloud correctly to non-
literate women. Women screened as eligible to participate
in the randomised feasibility trial will then be invited to
give written, informed consent to participate. As with
screening, non-literate women will signify their consent to
participate in the trial by witnessed finger print.
Due to potential risks of abusive partners learning of
women’s involvement, information sheets, consent forms and
Fig. 1 Flow diagram of problem solving therapy (PST) adapted for pregnant women experiencing intimate partner violence (IPV) feasibility trial
procedure, indicating the relationship with a nested feasibility trial of standard PST in women not reporting past-year IPV (shaded grey). ANC
antenatal care, HEW health extension worker, MINI Mini-International Neuropsychiatric Interview, PHQ-9 Nine-item Patient Health Questionnaire
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other study paperwork will be kept in the locked research of-
fice after being read and signed but will be accessible to
women at their request. Due to logistical challenges affecting
women’s daily lives in this setting, it is not possible to give
prospective participants 24 h to decide whether to take part.
However, a minimum of 30min will be allowed for the
woman to make up her mind about participating in the study.
Participant screening
Consecutive, potentially eligible women who provide in-
formed consent will be screened for depressive symptoms
and a history of past-year IPV after their ANC appoint-
ment. Depressive symptoms will be screened for using the
locally validated [58] nine-item Patient Health Question-
naire (PHQ-9) [59]. To screen for IPV exposure, research
staff will first read the introductory paragraph of the Am-
haric translated [60] Conflict Tactics Scale [61] to poten-
tial participants (or they may read themselves, if literate)
to ameliorate stigma they may feel towards disclosing IPV.
A five-item ‘non-graphic language’ screening test previ-
ously used in this and other LMIC contexts and found to
be a valid measure of IPV [62] will then be administered.
Finally, items from the WHO multi-country study [42] of
women’s health and domestic violence, previously used in
this setting, will be used to ask about experiences of IPV
in the past year.
All screened women scoring five or more on the
PHQ-9 [63, 64] and endorsing any functional impact of
symptoms (the tenth item) will be invited to participate
in the research study. Endorsement of the tenth item
will be defined as answering “somewhat”, “very” or “ex-
tremely difficult” to the question “over the last two
weeks, how difficult have these problems made it for you
to do your work, take care of things at home, or
get along with other people?”.
Consenting women who disclose any past-year IPV dur-
ing screening will be randomised to one of PST-IPV, stand-
ard PST or enhanced usual care, whereas consenting
women reporting no IPV on baseline measurements will be
randomised to one of standard PST or enhanced usual care
for the separate, nested PST feasibility trial (see Fig. 1).
Participant recruitment procedures
All women screened as eligible to participate will be in-
formed about the study and given the opportunity to ask
questions before being invited to consent to participate
in the randomised feasibility trial. Women consenting to
participate will first receive their routine clinical care
and then participate in a baseline interview using fully
structured questionnaires. If screening or this assess-
ment identify any sources of concern (e.g. suicidal idea-
tion, risks to herself or others), the researcher will
discuss these with the woman and explain the need to
share them with her health care professional, before
involving them. To be eligible to participate in the PST-
IPV components of the overall study, women must meet
the eligibility criteria (see below).
Participant eligibility criteria
Women can be included if they:
 Speak Amharic (the official regional language)
 Are aged 16 years or over
 Are between 12 and 34 weeks gestation of pregnancy
 Are intending to reside in the study area for the
duration of the study
 Score 5 or more on PHQ-9 with functional impair-
ment (tenth question)
 Report IPV in the past year (in a current or previous
relationship) during screening
 Consent to participate, including to accept enhanced
usual care or to attend four sessions of PST-IPV or
PST (if randomised to a treatment arm)
Women are required to speak Amharic, the official
language of the region, so that they can access all trans-
lated study materials, verbally or in writing. Relation-
ships are defined as any romantic or sexual interaction
within or outside marriage.
PHQ-9 has been validated in the study area in both
primary care [63] and ANC attendees (area under the re-
ceiver operating characteristic curve 0.91, 95% confi-
dence interval 0.86–0.96) [64]. For primary care
attendees a score of five or more was the optimal cut-off
for identifying possible depressive disorder. For antenatal
women, a cut-off of four or more was optimal. However,
since at the optimal cut-offs the positive predictive value
was less than 50%, in this study women scoring above
the cut-off (five or more) will be included if they also re-
port difficulty in their day-to-day activities (measured
using the PHQ-9 tenth item).
Participant exclusion criteria
Women will be excluded if they:
 Are acutely unwell
 Require emergency treatment
 Are identified by the ANC provider during pre-
screening as having possible psychotic symptoms
 Are unable to understand the interview (e.g.
diagnosed with severe intellectual disability or
dementia, or unable to speak Amharic)
 Expect to move away from the study area before the
study is completed
All women endorsing question nine of PHQ-9 about
suicidal thoughts or self-harm behaviours will receive
the Amharic [63] Mini-International Neuropsychiatric
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Interview suicidality scale [65]. Women scoring 17 or
above on the Mini-International Neuropsychiatric Inter-
view (indicating high suicide risk) will be excluded from
participation as part of a stepped-care model [54]. They
will be referred instead to a mental health-trained pri-
mary care worker who will employ mhGAP [55] criteria
to assess for imminent risk of self-harm or suicide.
Women assessed as being at imminent risk will be re-
ferred to a psychiatric nurse in the primary hospital for
escalation of their care. The attendance of participants
at referred appointments will be facilitated by the study,
including any attendant transportation costs to access
off-site services. Any psychotic symptoms and risks iden-
tified during the trial will be discussed with the project
mental health professional and women will be referred
for specialist mental health care if required. Women
assessed as eligible to participate at the time of screening
but who do not consent to take part will receive the
same stepped mental health care model, depending on
their symptoms and any imminent risks.
Otherwise eligible women reporting no past-year IPV
exposure will be invited to participate in the separate,
nested feasibility trial of standard PST for depression but
will not be eligible for this study of PST-IPV.
Participant consent
Interested women who cannot read will be read aloud
the information sheet. If unable to write, participants
will record a thumb print, signed by a literate witness (a
high school-educated assistant) after confirming that the
information sheet has been read aloud correctly; other-
wise, participants will provide written informed consent.
Study documents will be kept in the locked research of-
fice but will be accessible to women at their request.
The information sheet includes details of how partici-
pants can access compensation, if required.
Participant reimbursement
All participants will be reimbursed for their time attend-
ing research interviews in addition to transport costs
and any additional expenses incurred. Participants will
be reimbursed for transport costs to attend PST or PST-
IPV sessions but will not be compensated for their time
during these sessions. This is to determine the accept-
ability of psychological intervention sessions to women
and enable calculation of drop-out rates. A fund will be
available to assist participants disclosing IPV who wish
to access support services (for example. to facilitate
transport to a government social support office or police
station).
Randomisation and allocation to trial arms
Research staff will telephone the Centre for Innovative
Drug Development and Therapeutic Trials for Africa
data manager, based at the College of Health Sciences,
Addis Ababa University, Ethiopia, who is not otherwise
involved in this study, to allocate each participant to a
study arm (PST-IPV, standard PST or enhanced usual
care) using a random number list generated by the trial
statistician (GM), who is not otherwise involved in data
collection processes. The data manager will telephone a
separate member of research staff based in Silt’e, who
will inform a clinician trained to deliver PST-IPV or
standard PST when a new participant has been allocated
to that trial arm. Research staff will provide participants
with an unmarked card indicating their enrolment in the
trial and agree a date and time to attend their first ses-
sion of PST-IPV or standard PST. When they attend,
they will be expected by their allocated clinician. For
participants allocated to enhanced usual care, their ante-
natal care provider will provide them with information
about sources of support and the research assistant will
arrange a follow-up appointment 9 weeks later.
Women who do not attend their appointed date and
time will be contacted using the telephone number
(where applicable) and/or household details they have
provided at trial enrolment or through their allocated
HEW, up to a maximum of three attempts.
Masking
Given qualitative differences between PST and PST-IPV,
clinicians delivering the intervention cannot be masked
to participant allocation. To avoid contamination, PST-
IPV, standard PST and enhanced usual care will be de-
livered by different practitioners who have either
attended a PST-IPV or a standard PST training course,
or received basic training to provide enhanced usual
care. Post-intervention outcome assessments will be
conducted by trained, independent assessors (working in
separate offices from practitioners delivering interven-
tions and not travelling together) masked to intervention
allocation, with a minimum post-high school diploma
level of education. Independent assessors will document
any incidents of unmasking. Data analysts will also be
masked to intervention allocation.
Intervention arms
Participants randomised to PST-IPV or standard PST
will attend four intervention contacts within a maximum
of 8 weeks. Where birth occurs before the end of treat-
ment, the feasibility of continuing PST-IPV or standard
PST post-natally will also be assessed.
Both manualised interventions will be delivered by
trained health workers, such as nurses and midwives, su-
pervised by Psychology Masters-level qualified research
staff, with access to a project mental health professional
for clinical concerns. Responses to concerns and risk in-
cidents will follow standard operating procedures
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(SOPs). Government-employed health workers trained
to deliver the interventions will be paid for their time.
Both PST-IPV and standard PST intervention arms
follow the same structure of four sessions, based on the
model successfully employed in South Africa and
adapted for this rural Ethiopian setting [27, 66]. Session
1 focuses on basic psychoeducation, introduction to
PST, identifying the most important things in the
woman’s life and categorising problems into three
groups. Session 2 focuses on revising session 1, coping
strategies for ‘group A’ problems (which are upsetting
but do not influence the most important things in the
woman’s life) and the six-step problem solving method
for ‘group C’ problems (which are important and can be
solved). Session 3 focuses on revising session 2, coping
strategies for ‘group B’ problems (which are important
but cannot be solved) and psychoeducation about the
phases of coping with bereavement and loss. Session 4
focuses on revising session 3, using problem solving
skills in everyday life and reviewing how the coping
strategies worked in practice. All sessions involve assign-
ing and reviewing take-home activities.
PST-IPV content and materials are adapted to address
the needs and experiences of women affected by IPV,
whilst standard PST content and materials are generic.
Adaptations for women experiencing IPV include train-
ing staff using content and materials from the new
WHO curriculum on caring for women subjected to vio-
lence [67], attention to safety and sensitivity where
women list IPV-related problems during sessions (in-
cluding training with worked examples of problem solv-
ing focused on IPV), and adaptation of PST case studies
to reflect common problems associated with IPV.
Participants randomised to PST-IPV or standard PST
will attend a total of six contacts: one baseline pre-
intervention research assessment, four intervention con-
tacts and a follow-up research assessment contact 9
weeks after recruitment. The feasibility of follow-up 9
weeks after recruitment will be assessed and may
change, depending on gestation of pregnancy at the time
of enrolment.
Enhanced usual care arm
One-third of participants will be randomised to informa-
tion only about sources of support (enhanced usual care;
see Supplementary file 2). They will attend two contacts:
one pre-intervention assessment at which they are pro-
vided with information about relevant sources of sup-
port, and one follow-up assessment 9 weeks later.
In our meta-analysis we found that randomisation of
control group participants with depression, anxiety,
PTSD or psychological distress symptoms and IPV ex-
posure to waiting list, treatment as usual, or enhanced
usual care arms is widespread [21]. This, coupled with
the lack of any standard intervention provision for peri-
natal depression and/or IPV in rural Ethiopia and the
provision of safeguards in the study design, justify the
use of a control arm, which comprises enhanced usual
care (provision of information about sources of support).
Measurement: participants
Women will be assessed at baseline and then 9 weeks later
in a private room of the health care facility at a time con-
venient to them (Fig. 2). During these assessments, fully
structured measures will be administered to consenting
participants in an interview format. The time taken to
complete planned questionnaires will be tested prior to
commencing the study. Where administration of study
measures takes longer than 1 h per session or is experi-
enced by research staff or participants as unduly burden-
some, instruments will be removed from the assessment
questionnaire. This information will contribute to the
study’s process evaluation.
Primary participant outcome
At baseline and the independent, masked, 9-week
follow-up interview, depression symptoms will be mea-
sured using the Amharic-translated PHQ-9 [59], a nine-
item questionnaire asking about the presence of depres-
sive symptoms in the preceding 2 weeks. Each item is
rated according to persistence of the symptom (0 = not
at all, 1 = several days, 2 = more than half of the days,
3 = nearly every day). PHQ-9 scores pre- and post-
participation will be compared to calculate the mean dif-
ference in depression symptom reduction in PST-IPV,
standard PST and enhanced usual care arms. Propor-
tions of participants showing a treatment response, de-
fined as a 50% reduction in PHQ-9 score, will also be
calculated, although this feasibility trial will not be pow-
ered to detect treatment efficacy.
Secondary participant outcomes
At baseline and 9-week follow-up, the following will be
measured using Amharic-translated scales. If scores are
normally distributed, mean differences will be compared
between arms using t tests and, if not normally distrib-
uted, median differences will be compared between arms
using non-parametric statistical tests.
 Post-traumatic stress symptoms using the PTSD
checklist for the Diagnostic and Statistical Manual
version 5 (PCL-5) [68] which has been adapted for a
rural Ethiopian context
 Anxiety symptoms using the Generalised Anxiety
Disorder 7 (GAD-7) scale [69]
 Disability using the 12-item Ethiopian adaptation
[70] of the WHO Disability Assessment Schedule
(WHODAS 2.0) [71]
Keynejad et al. Trials          (2020) 21:454 Page 8 of 15
Fig. 2 Schedule of participant enrolment, interventions and assessments. CSRI client service receipt inventory, GAD-7 Generalised Anxiety
Disorder 7 scale, IPV intimate partner violence, MINI Mini-International Neuropsychiatric Interview, OSSS-3 Oslo Social Support Scale 3, PCL-5 post-
traumatic stress disorder checklist for Diagnostic and Statistical Manual version 5, PHQ-9 Nine-item Patient Health Questionnaire, PST problem
solving therapy, PTSD post-traumatic stress disorder, WHO World Health Organization, WHODAS World Health Organization Disability
Assessment Schedule
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 IPV: participants will be asked about past-month
IPV at baseline and 9-week follow-up to determine
whether the frequency of different types of IPV
(physical, sexual, psychological, coercive control)
change during the study period
 Self-efficacy using an adapted self-efficacy scale vali-
dated in Ethiopia for sexual health research [72]
 Mastery (the extent to which the person considers
themselves in control of forces affecting their lives in
important ways [73]) using a 15-item multi-cultural
mastery scale [74] adapted for rural, non-Western
communities
 Perceived social support using the Oslo Social
Support Scale 3 (OSSS-3) [75] previously used in
this region in a study of antenatal depressive
symptoms [46]
 Health care-seeking behaviour using the client service
receipt inventory [76] adapted for Ethiopia [77] and
modified to focus on the past month; the client service
receipt inventory will be used to quantify the frequency
of primary health care visits, inpatient admissions, pri-
vate sector (including traditional healer) contacts, med-
ications and investigations of women in each arm, in
the past month, pre- and post-participation
 Adverse events or unanticipated harms taking place
during the study period
 Obstetric and neonatal outcomes: HEWs, who
maintain maternal care records, will report the
location of birth and any stillbirths and early
neonatal deaths among study participants,
attendance at subsequent ANC appointments and
medication prescriptions for physical and mental
health, as they are not reliably self-reported [47];
where women attend ANC at a combination of
HEW health posts, health centres and/or primary
hospitals, antenatal contacts at all relevant services
will be collected; the feasibility of collecting this data
will be explored during analysis
 Attitudes towards gender roles using the WHO
Attitudes Towards Gender Roles questionnaire [42]
Measurement: process evaluation
Assessing parameters and feasibility for a future trial
The mixed-method process evaluation will assess variables as-
sociated with intervention implementation processes. Recom-
mended intervention process outcomes (for implementation)
include acceptability, adoption, appropriateness, feasibility, fi-
delity, implementation cost, penetration and sustainability
[78]. In this feasibility trial, we will focus on evaluating:
 Acceptability of PST-IPV and of the study design to
women and health workers in terms of uptake, com-
pletion and drop-out rates
 Adoption by health workers
 Appropriateness from women and health workers’
perspectives
 Feasibility in terms of practical organisation
 Fidelity of delivery
 Cost
 Safety
The following administrative data will be collected,
which will inform the feasibility outcome measures
shown in brackets:
 Screening rates and reasons for refusal
(acceptability)
 Recruitment rates (acceptability, feasibility)
 Numbers of eligible women at each clinical site
(appropriateness)
 Proportions of eligible women agreeing to
participate (acceptability)
 Willingness to be randomised and comprehension
by participants of randomisation (acceptability of
allocation)
 Session duration (appropriateness, feasibility, fidelity)
 Take-home activity completion (acceptability,
fidelity, appropriateness)
 Drop-out rates (acceptability, feasibility)
 Follow-up rates (feasibility of retention)
Research staff will document key site features to en-
able comparison of process data, and keep field journals
noting:
 Staff willingness to participate at each site and
retention in the study (acceptability, adoption,
appropriateness, feasibility)
 Optimal recruitment procedures (feasibility)
 Acceptance of randomisation at each site
(acceptability, appropriateness, feasibility)
Qualitative interviews
The acceptability and burden on women and staff of the
intervention itself (including which components are ex-
perienced as helpful or unhelpful), randomisation, out-
come measures and follow-up will be assessed through
qualitative interviews with a purposively sampled sub-
group of approximately six women (three per interven-
tion arm) and six staff (three per intervention arm). In-
terviews will also explore feasibility and acceptability of
the study’s SOP, which dictates the management of
safety, confidentiality and ethical concerns, risk disclo-
sures during sessions and research contacts. Interviews
will be conducted in Amharic by research staff who did
not have extended contact with participants during the
trial in a private location convenient to them. Partici-
pants will be compensated for their time, and interviews
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will be audio-recorded, transcribed and translated into
English.
Intervention fidelity and supervision
Health workers trained to deliver PST-IPV and standard
PST will receive monthly supervision with a local psychi-
atric nurse. Health workers will audio-record PST-IPV
and standard PST sessions with the participant’s consent
for review by their supervisor and to inform discussions
of challenging cases during supervision sessions.
A random sample of these audio recordings will be
evaluated using the ENACT scale [79] to assess therapist
competence (quality) alongside supervisor observations
and therapist logs. ENACT has been adapted for the
Ethiopian context and has been shown to be reliably ad-
ministered by trained clinicians [80].
Recordings will also be evaluated for intervention fi-
delity and session completion using a checklist of session
components. Supervision records and therapist logs will
also be reviewed for intervention fidelity and contamin-
ation between arms [27]. The frequency and duration of
IPV-specific content during recorded sessions of both
PST-IPV and standard PST documented in therapist
logs will also be noted to determine the extent to which
participants raise and explore IPV-related problems dur-
ing sessions. The quality of therapist–client rapport will
be assessed using the Amharic-translated helping alli-
ance questionnaire [81], which has been tested in this
setting [82].
Outcome assessors will receive supervision from a
Psychology Masters-qualified supervisor. Supervision
logs will include discussing any items which are poorly
understood or completed, and reviewing the time taken
for outcome assessment to assess its acceptability and
feasibility.
Statistical analysis
We will follow the Consolidated Standards of Reporting
Trials (CONSORT) extension to randomised pilot and
feasibility trials [83].
We will review process evaluation data for indications
of sub-group differences in uptake, recruitment and re-
tention of participants by site, health worker, recruit-
ment method/site, participant (age, education level,
religion, parity) and health worker characteristics (age,
profession, years of experience). Quantitative scale re-
sults will be analysed using STATA [84].
Feasibility studies are not powered to calculate effect
sizes but standard deviations and drop-out rates will be
calculated on the intention-to-treat sample (all women
who were randomised, regardless of uptake of the inter-
vention) to inform sample size calculation for a future
RCT, for outcome measures, recruitment rates and
drop-out rates. Quantitative process data will determine
future RCT design improvements, such as session num-
ber and duration, recruitment, outcome measures, and
strategies preventing contamination. The extent of miss-
ing data will be evaluated as part of the process evalu-
ation. For clinical outcome measures, missing data will
not be imputed. Rather, standard deviations will be cal-
culated using data from participants for whom outcome
measures are available.
We will apply the framework approach to thematic
analysis of qualitative interviews [85] and triangulate the
results with quantitative process data through researcher
meetings. The full descriptive analysis will include con-
textual barriers and facilitators influencing study
outcomes.
Ethical considerations
Strategies to ensure data protection, quality assurance
and dissemination of results are outlined in Supplemen-
tary file 3 and data collection forms are provided in Sup-
plementary file 4. Ethical approval has been provided by
the Institutional Review Board of the College of Health
Sciences, Addis Ababa University, Ethiopia (protocol
number: 032/19/CDT) and the Psychiatry, Nursing &
Midwifery subcommittee of King’s College London’s
College Research Ethics Committee, UK (reference: HR-
18/19–9230); see Supplementary file 5.
This study involves recruitment of potentially vulner-
able women, disclosure of IPV, and detecting depression,
anxiety and PTSD symptoms. The SOP therefore out-
lines actions to mitigate potential risks. If participants
disclose current exposure to IPV, research staff will be
trained to listen non-judgementally, offer privacy and
confidentiality, and information about local agencies
who can provide assistance (see Supplementary file 2)
[42] in keeping with WHO guidelines, irrespective of the
study arm.
Sensitivity
Female research staff will be carefully selected with the
sensitivity of subject matter in mind. Once recruited,
they will receive locally tailored IPV training [44]. When
approaching women, great sensitivity will be exercised.
In all cases, care will be taken to ensure that women do
not feel pressurised to participate. We will ensure ano-
nymity of interview transcripts and any quotations used
in publications or reports.
Safety
The SOP outlines measures to mitigate potential risks to
participants, including abusive partners learning of their
involvement. These include a protocol for responding to
concerns or disclosures of risk, emergency contact infor-
mation, conduct when communicating with vulnerable
participants, documenting and responding to serious
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adverse events and reporting them to the King’s College
London and Addis Ababa University institutional review
boards which have provided ethical approval for this
trial. Numbers of serious adverse events will be calcu-
lated per trial arm. A data monitoring committee will
not be instituted due to the small sample size of this
feasibility trial, which is not powered for interim
analyses.
Risk of harm
The risk of harm to participants will be minimised by
providing full information about the study prior to vol-
untary participation. Participants are free to withdraw
from taking part at any time without needing to give a
reason. Their individual data can be withdrawn from the
randomised feasibility trial until the final data collection,
at which point analysis will commence.
Some participants might become distressed when
speaking about their mental health or experiences of
IPV. Questions will be asked and worded sensitively to
minimise this occurring during research assessments.
During sessions of PST-IPV, the opportunity to express
emotion about problems and difficulties may be thera-
peutic, however. Clinicians will be trained in responding
to distress. Data collectors will be trained to be sensitive
to signs of distress and when to suggest rescheduling or
discontinuing an interview. If the participant remains
distressed, the data collector will contact their supervisor
and arrange appropriate support. If needed, women can
be referred to their ANC provider, who has been trained
in primary mental health care and the situation can be
discussed with the project mental health professional.
Discussion
Despite being an important social determinant of
physical and mental health, there is limited evidence
for brief, task-shared psychological interventions
adapted to address the mental health needs of women
experiencing IPV in LMICs. Interventions tailored to
the specific LMIC context and adapted to address the
experiences of women affected by IPV require devel-
opment, evaluation and implementation. This rando-
mised feasibility trial comparing PST-IPV with
standard PST and enhanced usual care in rural
Ethiopia and mixed-methods process evaluation will
determine feasibility and acceptability to women and
health workers to inform the design of a future RCT.
It will generate hypotheses, explore causal mecha-
nisms and contextual factors relevant to mental
health clinicians, researchers and implementation sci-
entists in primary care and ANC in LMICs, which
can be investigated across contexts in a future, fully
powered multi-centre RCT.
Strengths and challenges
This is the first study of its kind in this rural Ethiopian set-
ting. Most research into psychological interventions for
anxiety and depression in LMICs comes from urban or
peri-urban areas of middle-income countries, and only
two to date have been adapted for women experiencing
IPV [22, 23]. Neither of these interventions trialled a brief
intervention, embedded within ANC in a rural, low-
income country setting. The results will be informative to
researchers developing brief psychological interventions
adapted for this and other resource-restricted settings.
This three-arm randomised feasibility trial benefits
from a shared control group with a separate, nested
study of standard PST. The efficiency of shared control
groups is well documented [86] and multi-arm trials are
recognised for their simplicity, speed and reduced cost
relative to two-arm trials [87]. The study focus on evalu-
ating and refining the feasibility of both the PST-IPV
intervention and the study design using a mixed-method
process evaluation ensures that improvements will be
made prior to a definitive RCT.
The sensitivity of discussing mental health and IPV,
logistical challenges to women’s participation in re-
search, limited education and literacy and competing
priorities on ANC staff time are all anticipated chal-
lenges to the successful completion of this study. These
will be mitigated by stringent ethical conduct emphasis-
ing confidentiality and supporting women at risk of IPV,
supporting women to access intervention arms, adapting
recruitment and intervention procedures to accommo-
date variable education and comprehensive training and
supervision of health workers. However, unforeseen geo-
political eventualities may arise in rural, low-income set-
tings which compromise the conduct and completion of
this protocol as planned. The benefit of this feasibility
trial is to identify study design problems as early as pos-
sible in order to mitigate their impact on the resultant
research evidence.
Trial status
This is protocol version 1.0. This trial was prospectively
registered on the Pan-African clinical trials registry
(PACTR202002513482084) on 13 December 2019. Re-
cruitment of participants has not yet commenced. Re-
cruitment of participants is anticipated to complete by
31 December 2020. Any proposed changes to the proto-
col will be submitted to King’s College London and
Addis Ababa University ethics review boards and up-
dated on the pan-African clinical trials registry. Re-
search staff will inform trial participants, where
required, and changes will be discussed in the ultim-
ate results publication. The trial sponsor is King’s
College London, De Crespigny Park, Denmark Hill,
London SE5 8AF, UK.
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